美中藥協
SAPA
SAPA-NE
新英格蘭美中藥協
www.SAPA-NEweb.org

24th SAPA-NE Annual Conference

New Era and Unprecedented Opportunities for Developing Novel Therapies

September 24th, 2022
9am – 4pm EDT
via Zoom

Greeting Message from the SAPA-NE President

Dear SAPA Members and Friends:

Welcome to the 24th SAPA-NE Annual Conference, New Era and Unprecedented Opportunities for Developing Novel Therapies. This year's conference comprises a full-day scientific program that focuses on RNAi Based Therapeutics and Novel RNA Bioengineering. The event features a series of lectures and presentations as well as panel discussions to be delivered by distinguished experts and leaders from both academic and industry on the following topics:

- *Future of Drug Discovery and Development*
- *New Modality Platforms and Frontiers*
- *Enabling Technology Advancement and Applications*
- *Targeted Drug Delivery and Regulatory Issues*

SAPA-NE Annual Conference is a great platform for participants to share their knowledge, wisdom, and viewpoints on science, technology, and business in the biomedical/pharmaceutical field. On behalf of the annual conference organizing committee, I would like to thank all the keynote speakers and conference sponsors who have made this exciting program possible. Regardless of your interest in the subject matter, you would find their talks in the program stimulating and insightful, which may help to generate new ideas, innovations, and collaborations in your drug discovery and development efforts.

SAPA is a non-profit organization founded in 1993 for pharmaceutical professionals. SAPA has more than 4000 members from USA, China, and other Asian regions. SAPA's mission is to serve its members and foster their career development through conference/symposium/networking, and to ultimately help to find new solutions in treating many challenging diseases. SAPA-NE is a SAPA chapter in New England. It was founded in 1998 in Boston, now one of the world centers for pharmaceutical/biotech innovation. Currently it serves more than 1000 pharmaceutical/biotech R&D professionals (www.sapa-neweb.org).

Enjoy the conference and wish you a productive and enlightening day!!

Sincerely,

Haiying Liu, Ph.D
SAPA-NE President
www.SAPA-NEweb.org

Sino-American Pharmaceutical Professionals Association–New England

President	James Cao, Ph.D., Sanofi
President-Elect	Haiying Liu, Ph.D., Janssen Pharmaceutical Companies
Immediate-Past President	Guiqing Liang, Ph.D., Vertex Pharmaceuticals
Secretary General	Kehao Zhao, Ph.D., Elpis Biopharmaceuticals

Conference Chairs (alphabetized by last name)

Haiying Liu, Ph.D., Janssen Pharmaceutical Companies

Executive Committee Member

Xingfeng Bao, Ph.D., H3 Biomedicine
Joyce Chen, MBA, M.S., Kintor Pharmaceutical
Shizhe Hui, M.S., IHISTO
Huijuan Li, Ph.D., Moderna
Lin Lin, Ph.D., BIDMC, MinJiang University
Mingde David Shan, Ph.D., Eisai
Zhen Tong, Ph.D., Bristol-Myers Squibb
Dong Yang, Ph.D, Bristol-Myers Squibb
Tracy Yuanfan Zhang, Ph.D., Sanofi
Yu Chen, M.PHIL., MBA WUXI
Yuan Hu, Ph.D., Alkermes
Haishan Li, Ph.D., Perkin Elmer
Kejie Li, Ph.D., Stealth NewCo
Pei Ma, Ph.D., Foundation Medicine
Peng Sun, Ph.D., JD, Sarepta Thx
Wenyu Wang, Ph.D., Vertex
Hongwei Howie Zhang, Ph.D., Laronde
Jun Zhao, M.S., Merck

Advisory Committee Member

Kechun Li, Ph.D., Yuanming Capital
Min Chen, Ph.D., Novartis
Jenny Li, Ph.D., First Capital
Qingcong Lin, Ph.D., Biocytogen
Yonchun Shen , Ph.D., Eisai
Derek Tou, M.D., Ph.D., Hikewell
Guiqing Liang, Ph.D., Novartis
Mark Lin, Ph.D., Board Member, Takeda
Nanding Zhao, Ph.D., MBA, Kanova Biopharmaceutical
Larry Cai, MBA, M.S., Fosun Pharma USA
Dapeng Chen, PhD. KSQ Therapeutics, Inc.
Bingli Ma, M.D., Sanofi
Daming Gou, Ph.D., Proton USA J-Star Research
Huo Li, Ph.D., Board Member, 风投基金
Wenge Wang, Pfizer
Huimin Chen, GSK
Xiaotian Zhong, Ph.D., Pfizer
Jiang Long, Ph.D., Enanta

Agenda

Time	Keynote Speech
9:00-9:05 AM	**Opening Remarks**
Session 1: Future of Drug Discovery and Development Moderator: Dr. Haiying Liu	
9:05-9:40 AM	Dr. Hong Shen, SVP, Roche China The journey of the China Innovation Center of Roche (CICoR)
9:40-10:15 AM	Dr. Tommy Vaughan, Professor, Columbia University MRI for the World
10:15-10:20 AM	**Break (5min)**
Session 2: New Modality Platforms and Frontiers Moderators: Dr. Mingde Shan, Dr. Yu Chen, Dr. Tracy Zhang, and Dr. Haiying Liu	
10:20-10:50 AM	Dr. Leo Qian, Co-Founder and VP, Entrada Therapeutics Endosomal Escape Vehicle (EEV) Platform to Enhance the Functional Delivery of Oligonucleotides
10:50-11:20 AM	Dr. Steve Kates, VP, Regulatory Affairs, Dicerna GalXC™ and GalXC-Plus™ RNAi Technologies: From Bench to Clinic
11:20-11:40 PM	Dr.Guoqiang Wang, VP, Chemistry, Ranok Therapeutic Chaperone-mediated Protein Degradation (CHAMP™): A Tumor-targeted Protein Degrader Technology
11:40-12:10 PM	Dr. Shuling Guo, VP, Ionis Pharmaceuticals RNA Therapeutics--A Versatile Drug Discovery Platform
Career Development Panel Discussion (BMS) & Lunch Break	
12:10-1:00 PM	Successful Career in Bio-Pharmaceutical Industry
Session 3: Enabling Technology Advancement and Applications Moderators: Dr. Huijuan Li, Dr, Haishan Li and Dr. Pei Ma	
1:00-1:20 PM	Dr. James Jin, VP, Biocytogen Boston Corp Gene Engineered Mouse Models (GEMMs) in Drug Discovery
1:20-1:40 PM	Dr. Chris Moore and Dr. Zach Houston, Perkin Elmer Visualizing the Effects of Therapy with Vega and IVIS Preclinical Imaging Platforms
1:40-2:00 PM	Dr. Santi Chen, Associate Director, GemPharmatech Supporting Preclinical Research and Drug Development with Cutting-Edge GEMMs and Services
2:00-2:05 PM	**Break (5min)**
Session 4: Targeted Drug Delivery Moderators: Dr. Hongwei Zhang and Dr. Mingde Shan	
2:05-2:40 PM	Dr. Qiaobing Xu, CEO, Hopewell Therapeutics/Professor, Tufts University Synthetic Biodegradable Lipid Nanoparticles for Gene Therapy and Gene Editing
2:40-3:15 PM	Mr. Saket Agarwal, Scientist, Alnylam Pharmaceuticals Recent Advances in Delivery of RNAi Therapeutics to the CNS
3:15-3:20 PM	**Closing Remarks**
3:20-4:00 PM	**SAPA-NE Business Session: Awards and SAPA-NE Business**

Speaker Biography

Hong Shen, Ph.D.

SVP and Head of China Innovation Center of Roche (CICoR)

Dr. Hong Shen received his Ph.D. from Stanford University. After 9 years working at Merck in the US, Dr. Shen joined the Roche R&D Center in Shanghai. He is currently Senior Vice President, Head of China Innovation Center of Roche (CICoR), leading an organization of over 230 colleagues for drug research and early development. Dr. Shen has drug discovery experience relevant to the therapeutic areas of oncology, immunology, antiviral, antibiotics, hypertension, diabetes, thrombosis, atherosclerosis, and obesity. His organization has major contributions to 7 clinical compounds and over a dozen of preclinical candidates in the past 10 years. Dr. Shen has 110 publications and over 110 patent applications. He is a Fellow of the Royal Society of Chemistry (FRSC), a member of the AACR Chemistry in Cancer Research Working Group (CICR) Steering Committee, an extended core member of the R&D-based Pharmaceutical Association Committee (RDPAC) in China, and a lecturer at several universities. Dr. Shen is a recipient of the Zhangjiang Outstanding Innovation and Entrepreneurship Award in China, and Leo Sternbach Award as well as pRED Inventor's Recognition Gold Medal at Roche.

Tommy Vaughan, Ph.D

Professor, Columbia University

Thomas Vaughan began his career with NASA followed by Texas Instruments, designing and building microwave radar systems. While pursuing his post graduate education at UT Southwestern, he applied his high-frequency radar knowledge to building the first 2T NMR system for human imaging and spectroscopy in 1984. This was followed by the first 4T system with Philips and UAB in 1990, the first two 7T systems at Harvard/MGH and the University of Minnesota, and the first 9.4T and 10.5T MR systems for humans at Minnesota. As the founding Director of the Columbia MR Research Center, Dr. Vaughan is now working with engineers and physicists from industry and academics to build an NSF sponsored, second generation 9.4T neuroimager to serve the Greater New York neuroscience community. This shared resource will be centrally sited and supported by the New York State Nathan Kline Institute. While building some of the world's most powerful MR systems for science has led to significant achievements, the most important goal remains unmet. According to the WHO, two thirds of the world does not yet have access to MR for science or medicine. "Tommy" and his colleagues at Harvard, Yale, Mt. Sinai, and Columbia have turned their attention to solving this problem. Their solutions to achieving "MRI for the World" will be the topic of his talk.

Speaker Biography

Ziqing "Leo" Qian, Ph.D.

Vice President, Discovery Research, Entrada

Ziqing "Leo" Qian, Ph.D. is co-founder and Vice President, Discovery Research at Entrada Therapeutics, a Boston-based biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular therapeutics. Dr. Qian co-invented Entrada's Endosomal Escape Vehicle (EEV™) platform, which is applied to the design and development of intracellular delivery of otherwise impermeable biological cargos, including oligonucleotides, proteins, and peptides. Leo obtained his Ph.D. in Organic Chemistry from The Ohio State University.

Steve Kates, Ph.D

VP Regulatory Affairs, Dicerna

Steven Kates is Vice President of Regulatory Affairs at Dicerna Pharmaceuticals a wholly owned subsidiary of Novo Nordisk located in Lexington Massachusetts. He is a highly experienced pharmaceutical executive with over thirty years in R & D for both human therapeutics and life science products and has advanced several compounds through drug development from early pre-clinical to early clinical development and approval. He has held senior positions at Takeda, Lakewood Amedex, Ischemix, Citius Pharmaceuticals, Surface Logix, Consensus and Millipore Corporation. Dr. Kates is a world-leading chemist and industry expert in peptide design and manufacture. He has written or co-authored more than 100 articles, reviews, and patents. Dr. Kates has served as editor of two books entitled Solid-Phase Synthesis: A Practical Guide and ADMET for Medicinal Chemists, A Practical Guide; guest editor of Biopolymers; and as a member of the Editorial Board of International Journal of Peptide Research and Therapeutics. A Part-Time Assistant Professor at Northeastern University College of Professional Studies in Regulatory Affairs and Visiting Professor of Chemistry at Brandeis University, Dr. Kates earned his B.S. in chemistry from Bates College, Ph.D. in Synthetic Organic Chemistry from Brandeis University and conducted post-doctoral studies at The Massachusetts Institute of Technology.

Speaker Biography

 **Shuling Guo, Ph.D.** VP Drug Discovery, Ionis Pharmaceuticals	*Dr. Shuling Guo received her Ph.D. in Molecular Cancer Biology from Duke University and had her postdoctoral training at HHMI/UCLA. Since joining Ionis Pharmaceuticals in 2008, Dr. Guo has been taking on steadily increasing responsibilities, now serving as the Vice President of Drug Discovery. Dr. Guo oversees the overall drug discovery efforts in CardioRenal, Metabolic, and Pulmonary franchises. She manages research activities from target identification, target validation, to the selection of human development candidates. In addition, she is closely involved in the clinical development of RNA therapeutics. Furthermore, over the years, Dr. Guo has managed exploratory research activities including noncoding RNA, autophagy/mitophagy, and nonsense-mediated mRNA decay. To date, Dr. Shuling Guo has published over 70 articles, a majority of which are related to the applications and mechanisms of antisense technology in various therapeutic areas.*
 **Guoqiang Wang, Ph.D.** Vice President, Ranok Therapeutic	*Dr. Wang received his Ph.D. in organic chemistry from Institute of Chemistry, Chinese Academy of Science and completed postdoctoral fellowships in Massachusetts Institute of Technology and Kao Research Institute, Japan. Since joining Enanta Pharmaceuticals in 1999, he had been taking increased responsibilities and served as executive director of medicinal chemistry before leaving. In over 22 years in Enanta Pharmaceuticals, Dr. Wang led a group of medicinal chemists and discovered over six candidate compounds which reached different clinical stages. Among them, the HCV protease inhibitor compound -- Glecaprevir which in combination with Pibrentasvir, was approved by FDA and marketed as MAVYRET™ in 2017. MAVYRET™ is one of the best treatment for HCV patient with only 8 weeks treatment duration. Dr. Wang joined Ranok Therapeutics in 2022 and is leading medicinal chemistry effort in creating next generation of safer and more efficacious cancer therapies using CHAMP™ platform. He has co-authored over 50 publications/presentations and listed as inventor/co-inventor on over 70 filed US patent applications.*

Speaker Biography

 **James Jin, Ph.D.** Vice President, Biocytogen	*Dr. James Jin received his PhD in Virology at Wuhan University in 1997. After his postdoctoral training at Colorado State University,. he worked as a Research Assistant Professor at the University of Illinois at Chicago from 2005 to 2010. In 2010, he was recruited to Advanced Cell Technology, Inc. as a Senior Scientist. Dr. Jin joined Biocytogen as the Director of Technology in 2011, where he was promoted to vice president. His research expertise spans the fields of virology, immunology, proteomics, protein structure, human stem cell, and genetic engineering.*
 **Santi Chen, Ph.D.** Associate Director, GemPharmatech	*Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children's Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.*

Speaker Biography

 **Chris Moore, Ph.D.** PerkinElmer	*Dr. Chris Moore from PerkinElmer is an imaging expert with ten years' experience developing tools for drug developers and patients in the clinic. Chris brings background in clinical ultrasound elastography to the preclinical space to streamline the path from drug development to patient care.*
 **Zach Houston, Ph.D.** PerkinElmer	*Dr. Zach Houston has more than 8 years' experience in preclinical and translational multimodal imaging towards the development of novel biologics, chemotherapeutic and radiotherapeutics. He currently applies his expertise in bioluminescent imaging, fluorescent imaging, MRI, CT and PET to help researchers better understand their therapeutic and diagnostic developments using PerkinElmer's comprehensive suite of instrumentation.*

Speaker Biography

 **Qiaobing Xu, Ph.D.** Professor, Tufts University; Founder and CEO, Hopewell Therapeutics	*Dr. Qiaobing Xu is professor in Department of Biomedical Engineering at Tufts University. He is also the founder and CEO of Hopewell Therapeutics. He obtained his B.S. from Jilin University, Changchun, China, and PhD from Harvard University, USA. He did a postdoc training at MIT before joining Tufts as an assistant professor in September 2010. He was promoted to full professor in 2021. His research group mainly focuses on developing novel synthetic biodegradable lipids for nucleic acid delivery, including gene therapy and gene editing. He received Charlton Award from Tufts University School of Medicine in 2012 and named the Pew Scholar for Biomedical Sciences from Pew Charitable Trusts in 2013. He received the National Science Foundation CAREER Award in 2015. He was elected as a Fellow of AIMBE, class of 2020.*
 **Saket Agarwal** Scientist, Investigative Toxicology, Alnylam Pharmaceutical	*Saket Agarwal is a Scientist working with the Investigative Toxicology group at Alnylam Pharmaceuticals. In his current role, he leverages his background in cell & molecular biology to understand the mechanisms related to potential siRNA toxicity, using simple and complex in-vitro models, and non-clinical animal species. Prior to Alnylam, he worked with small molecules conducting early target discovery/validation and developed high throughput assays for large compound library screening. Saket earned his Bachelor's and Master's in Biological Sciences from Drexel University.*

Silver Sponsors

BIOCYTOGEN

Bristol-Myers Squibb

GemPharmatech™

PerkinElmer
For the Better

RANOK Therapeutics

Learn More About SAPA-NE

Please visit https://www.sapa-neweb.org or scan the following WeChat QR code. Group admin (Kejie Li) will invite you to join us.

INNOVATIVE SOLUTIONS TO ACCELERATE ANTIBODY DISCOVERY

Humanized Mouse Models

- Humanized Immune Checkpoint Mice
- Immunodeficient B-NDG Mice for Xenograft Studies
- Humanized Cytokine & GPCR Mice
- Humanized Tumor Cell Lines

Antibody Discovery

- Fully Human Therapeutic Antibodies, Surrogates, Anti-idiotype & Bispecific/Multispecific Antibodies
- Single B Cell Cloning Technology
- Best-In-Class Fully Human Antibody Mouse



Pharmacology Services

- Expertise in Efficacy Evaluation of Novel Therapeutics
- In Vitro Studies, In Vivo Assays, PK, PD, Toxicity Assessments

Gene Editing Services

- CRISPR/Cas9-Based Extreme Genome Editing (EGE™)
- ESC-Based Homologous Recombination (Large Fragments)
- Models or Cell Lines

OUR INTEGRATED SERVICES

百奥赛图
BIOCYTOGEN

OUR EXPERTISE

1,200 Strains of **BIOMICE**

10-20 FOLD
Increased Knock-In Efficiency with EGE™

820+ DRUG EVALUATION PROJECTS
Delivered Annually

INDUSTRY-LEADING
Single B Cell Screening Technology

ABOUT US

- **1,200+** Employees Worldwide
- **2,000+** Partners & Clients ← **1,500+** ACADEMIC, **500+** INDUSTRIAL
- **9** of the **TOP 10** Pharmaceutical companies use our models and/or services

View our models page and full catalog:

www.biocytogen.com

RANOK Therapeutics

DISCOVERING A BETTER TOMORROW FOR CANCER PATIENTS & THEIR FAMILIES

- Clinical-stage, oncology-focused biotech:
  - Waltham, MA USA – HQ & clinical team
  - Hangzhou & Shanghai, China – R&D team
- Innovative tumor-selective CHAMP™ targeted protein degradation platform
- Most advanced program in Phase 1/2 clinical trial in USA for solid tumors & lymphoma
- Currently hiring:
  - CMO (Waltham)
  - Head of Biology (Hangzhou)
  - Sr. Scientist, Proteomics (Hangzhou)
  - Sr. Scientist, Translational Res. (Waltham)

www.RanokTherapeutics.com

Notes